| A | B | C | D | E | F | G | H | |
|---|---|---|---|---|---|---|---|---|
| 1 | Main | |||||||
| 2 | Brand | Keytruda, fka MK-3475 | ||||||
| 3 | Generic | pembrolizumab | ||||||
| 4 | Indications | NSCLC, Melanoma | ||||||
| 5 | Mechanism | PD-1 mab | ||||||
| 6 | IP | 2028? | ||||||
| 7 | Clinical Trials | |||||||
| 8 | KEYNOTE-869 | Phase Ib/II "EV-103" Cohort K | 1L mUC cisplatin-ineligible | n=76 with efortumab vedotin | 64.5% ORR vs. 45% ORR with EV alone | NCT03288545 | ||
| 9 | KEYNOTE-905 | EV-303 | NCT03924895 | |||||
| 10 | KEYNOTE-A39 | EV-302 | NCT04223856 | |||||
| 11 | KEYNOTE-B15 | EV-304 | NCT04700124 |